Biomea Fusion Inc

NASDAQ BMEA

Data sourced from

and

Download Data

Biomea Fusion Inc Non-Cash Items (Other) 2 year CAGR for the year ending December 31, 2023: 432.63%

Biomea Fusion Inc Non-Cash Items (Other) 2 year CAGR is 432.63% for the year ending December 31, 2023, a 208.74% change year over year. Non-Cash Items (Other) are non-cash expenses or gains that impact a company's financial statements, excluding depreciation and amortization. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Biomea Fusion Inc Non-Cash Items (Other) for the year ending December 31, 2022 was USD 715.00 K, a 1.56% change year over year.
Biomea Fusion Inc Non-Cash Items (Other) for the year ending December 31, 2021 was USD 704.00 K, a 467.74% change year over year.
Biomea Fusion Inc Non-Cash Items (Other) for the year ending December 31, 2020 was USD 124.00 K.

NASDAQ: BMEA

Biomea Fusion Inc

CEO	Mr. Thomas Andrew Butler
IPO Date	April 16, 2021
Location	United States
Headquarters	900 Middlefield Road, Redwood City, CA, United States, 94063
Employees	110
Sector	Healthcare
Industry	Biotechnology

Description

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Key trends